Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties

Cancer Research

Volumn 59, Issue 12, 1999, Pages 2939-2943

  Lesueur Ginot, Laurence ^a   Demarquay, Danièle ^a   Kiss, Robert ^c   Kasprzyk, Philip G ^b   Dassonneville, Laurent ^d   Bailly, Christian ^d   Camara, José ^a   Lavergne, Olivier ^a   Bigg, Dennis C H ^a  

^a Institut Henri Beaufour   (France)

^b Biomeasure Inc   (United States)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d Institut de Recherche sur le Cancer de Lille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; HOMOCAMPTOTHECIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STABILITY; DRUG TARGETING; ENZYME INHIBITOR INTERACTION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA; LEUKEMIA L 1210; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL DIVISION; DISEASE MODELS, ANIMAL; DNA; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; ENZYME INHIBITORS; HT29 CELLS; HUMANS; K562 CELLS; LACTONES; LEUKEMIA L1210; LEUKEMIA, EXPERIMENTAL; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033564494     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Wall, M. E., and Wani, M. C. Camptothecin and analogs: from discovery to clinic. In: M. Potmesil and H. M. Pinedo (eds.), Camptothecins: New Anticancer Agents, pp. 21-41. Boca Raton, FL: CRC Press, 1995.
2. Rothenberg, M. L. Topoisomerase 1 inhibitors: review and update. Ann. Oncol., 8: 837-855, 1997.
3. Lavergne, O., and Bigg, D. C. The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan. Bull. Cancer (Paris), Spec No 1: 51-58, 1998.
4. Muggia, F. M. Twenty years later: review of clinical trials with camptothecin sodium. In: M. Potmesil and H. M. Pinedo (eds.), Camptothecins: New Anticancer Agents, pp. 43-50. Boca Raton, FL: CRC Press, 1995.
5. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Maltern, M. R., Mong, S. M., Bartus, J. O., Johnson, R. K., and Kingsbury, W. D. Modification of the hydroxy lactone ring of camplothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32: 715-720, 1989.
6. Nicholas, A. W., Wani, M. C., Manikumar, G., Wall, M. E., Kohn, K. W., and Pommier, Y. Plant antitumor agents. 29. Synthesis and biological activity of ring D and ring E modified analogues of camptothecin. J. Med. Chem., 33: 972-978, 1990.
7. Crow, R. T., and Crothers, D. M. Structural modifications of camptothecin and effects on topoisomerase I inhibition. J. Med. Chem., 35: 4160-4164, 1992.
8. Redinbo, M. R., Stewart, L., Kuhn, P., Champoux, J. J., and Hol, W. G. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science (Washington DC), 279: 1504-1513, 1998.
9. Fan, Y., Weinstein, J. N., Kohn, K. W., Shi, L. M., and Pommier, Y. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. J. Med. Chem., 41: 2216-2226, 1998.
10. Burke, T. G. Chemistry of the Camptothecins in the bloodstream. Drug stabilization and optimization of activity. Ann. NY. Acad. Sci., 803: 29-31, 1996.
11. Cao, Z., Harris, N., Kozielski, A., Vardeman, D., Stehlin, J. S., and Giovanella, B. Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. J. Med. Chem., 41: 31-37, 1998.
12. Lavergne, O., Lesueur-Ginot, L., Pla Rodas, F., and Bigg, D. C. H. BN 80245: an E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorg. & Med. Chem. Lett., 7: 2235-2238, 1997.
13. Lavergne, O., Lesueur-Ginot, L., Pla Rodas, F., Kasprzyk, P. G., Pommier, J., Demarquay, D., Prévost, G., Ulibarri, G., Rolland, A., Schiano-Liberatore, A. M., Harnett, J., Pons, D., Camara, J., and Bigg, D. C. H. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J. Med. Chem., 41: 5410-5419, 1998.
14. Burke, T. G., Munshi, C. B., Mi, Z., and Jiang, Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs (published erratum appears in J. Pharm. Sci., 84: 1492, 1995.). J. Pharm. Sci., 84: 518-519, 1995.
15. Burke, T. G., and Gao, X. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J. Pharm. Sci., 83: 967-969, 1994.
16. Chen, A. Y., Yu, C., Potmesil, M., Wall, M. E., Wani, M. C., and Liu, L. F. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res., 51: 6039-6044, 1991.
17. Mitsui, I., Kumazawa, E., Hirota, Y., Aonuma, M., Sugimori, M., Ohsuki, S., Uoto, K., Ejima, A., Terasawa, H., and Sato, K. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn. J. Cancer Res., 86: 776-782, 1995.